These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34439290)

  • 1. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.
    Llinàs-Arias P; Íñiguez-Muñoz S; McCann K; Voorwerk L; Orozco JIJ; Ensenyat-Mendez M; Sesé B; DiNome ML; Marzese DM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
    Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present and Future of Immunotherapy for Triple-Negative Breast Cancer.
    Sriramulu S; Thoidingjam S; Speers C; Nyati S
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
    Zhou L; Yu CW
    Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance.
    Bai X; Ni J; Beretov J; Graham P; Li Y
    J Natl Cancer Cent; 2021 Sep; 1(3):75-87. PubMed ID: 39036372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
    Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
    Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
    Shi J; Liu F; Song Y
    Cancer Manag Res; 2020; 12():9375-9387. PubMed ID: 33061626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
    Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
    Front Oncol; 2021; 11():648139. PubMed ID: 34094935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
    Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
    Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
    Elizabeth MS; Cristina SBJ; Christian CG
    Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Immunotherapy for Breast Cancer: A Review.
    Wen QE; Li L; Feng RQ; Li DH; Qiao C; Xu XS; Zhang YJ
    Breast Cancer (Dove Med Press); 2024; 16():497-516. PubMed ID: 39220564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.
    Stagg J; Allard B
    Ther Adv Med Oncol; 2013 May; 5(3):169-81. PubMed ID: 23634195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
    Ayoub NM; Al-Shami KM; Yaghan RJ
    Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Triple-Negative Breast Cancer.
    Cao Y; Chen C; Tao Y; Lin W; Wang P
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.